Among these patients, 91 had RET fusion-positive NSCLC, 23 had RET-mutant MTC, 7 had RET fusion-positive PTC, and 1 had RET-mutant gastric cancer. This evidence concerns the gene RET and medullary thyroid gland carcinoma.